Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,028 total abstracts
  1. Abstract 97582026-06-01 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-725 study)
    C. Robert, F. Andre, C. Saura, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 94262026-06-04 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-366
    P. Schmid, S. Modi, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 91962026-06-05 · 16:00 CT · Arie Crown Theater
    CheckMate-608: Opdivo (nivolumab) 1L in NSCLC
    L. Paz-Ares, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 95182026-06-01 · 13:30 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    J. Brahmer, P. Schmid, M. Reck, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 90682026-06-03 · 15:45 CT · S100A
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-819
    H. Borghaei, M. Reck, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 94562026-06-04 · 21:00 CT · E450
    FLAURA-959: Tagrisso (osimertinib) 1L in NSCLC
    S. Modi, H. Rugo, J. Cortes, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 98672026-06-03 · 16:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-45
    A. Spira, P. Schmid, S. Modi, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 92482026-06-03 · 18:45 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    M. Reck, C. Saura, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  9. Abstract 98932026-06-05 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-149 study)
    L. Paz-Ares, C. Saura, A. Spira · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 90962026-06-05 · 13:15 CT · Hall B1
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-598
    G. Curigliano, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 92152026-06-05 · 19:45 CT · S406
    CheckMate-925: Opdivo (nivolumab) neoadjuvant in NSCLC
    G. Curigliano, C. Saura, M. Krop, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 98042026-06-02 · 13:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-693
    H. Rugo, E. Winer, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 99102026-06-05 · 13:45 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    H. Borghaei, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 94732026-06-04 · 19:00 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    M.C. Garassino, J. Cortes, R. Herbst, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 93742026-06-01 · 13:45 CT · S406
    Quality of life outcomes with Keytruda in patients with NSCLC
    C. Robert, M. Reck · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 91332026-06-04 · 21:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-337
    S. Modi, G. Curigliano, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 98932026-06-03 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-73 study)
    H. Borghaei, P. Schmid, S. Tolaney, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 92682026-06-03 · 15:00 CT · S406
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-484
    S. Modi, A. Spira, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 98242026-06-02 · 15:30 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-8 study)
    P. Schmid, T. Mok, J. Brahmer · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 99632026-06-05 · 13:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-656
    R. Herbst, C. Saura, S. Modi, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  21. Abstract 99252026-06-03 · 15:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-788
    G. Curigliano, T. Mok, E. Winer, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 92332026-06-03 · 19:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-435
    J. Cortes, T. Mok, S. Peters · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  23. Abstract 91492026-06-02 · 14:00 CT · Arie Crown Theater
    PACIFIC-990: Imfinzi (durvalumab) 2L in SCLC
    C. Robert, H. Borghaei, H. Rugo, et al. · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  24. Abstract 98702026-06-05 · 18:45 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    F. Andre, A. Spira, R. Herbst, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 91372026-06-01 · 20:30 CT · S406
    FLAURA-443: Tagrisso (osimertinib) 2L in NSCLC
    L. Paz-Ares, P. Schmid, F. Andre, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 93482026-06-05 · 19:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-940 study)
    C. Robert, S. Tolaney, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 91242026-06-05 · 16:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-382
    N. Rizvi, A. Spira, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  28. Abstract 97752026-06-03 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for NSCLC: DESTINY-Breast-276
    S. Tolaney, N. Rizvi · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 99802026-06-05 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    S. Antonia, C. Saura · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  30. Abstract 90662026-06-03 · 19:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-66
    A. Spira, F. Andre, E. Winer · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 97642026-06-02 · 14:45 CT · S406
    CheckMate-315: Opdivo (nivolumab) 2L in NSCLC
    R. Herbst, S. Modi · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 95842026-06-02 · 16:15 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    E. Winer, M. Krop · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 92612026-06-02 · 19:45 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-876
    N. Rizvi, S. Modi, M. Reck, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 99982026-06-03 · 20:30 CT · S406
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-575
    M. Krop, S. Antonia · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 91692026-06-02 · 13:30 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    H. Borghaei, J. Brahmer · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 98272026-06-03 · 21:45 CT · Hall B1
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-223
    J. Brahmer, C. Saura, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 99592026-06-04 · 20:15 CT · E450
    Quality of life outcomes with Tecentriq in patients with NSCLC
    S. Antonia, A. Spira, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 97842026-06-05 · 18:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-970
    T. Mok, G. Curigliano, J. Cortes · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 91102026-06-05 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-795
    L. Paz-Ares, M. Reck, C. Saura, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 94112026-06-02 · 20:45 CT · E450
    PACIFIC-965: Imfinzi (durvalumab) 3L+ in SCLC
    C. Saura, J. Cortes, S. Tolaney · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  41. Abstract 99482026-06-03 · 20:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-528 study)
    L. Paz-Ares, H. Borghaei · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 90622026-06-02 · 16:30 CT · Hall B1
    IMpower-571: Tecentriq (atezolizumab) adjuvant in NSCLC
    F. Andre, G. Curigliano, J. Brahmer, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 95232026-06-01 · 13:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-276
    N. Rizvi, P. Schmid, H. Rugo, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 97442026-06-03 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-43 study)
    G. Curigliano, S. Antonia, T. Mok, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  45. Abstract 98732026-06-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-625 study)
    R. Herbst, S. Antonia, J. Brahmer, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 98442026-06-05 · 14:45 CT · E450
    CheckMate-56: Opdivo (nivolumab) 2L in NSCLC
    S. Tolaney, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 93352026-06-05 · 21:45 CT · E450
    FLAURA-428: Tagrisso (osimertinib) 3L+ in NSCLC
    C. Robert, G. Curigliano, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 93502026-06-04 · 19:45 CT · S406
    FLAURA-825: Tagrisso (osimertinib) 3L+ in NSCLC
    H. Rugo, R. Herbst, S. Peters, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 96512026-06-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-563 study)
    M. Krop, A. Spira · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 98862026-06-03 · 16:15 CT · S406
    IMpower-68: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    S. Antonia, S. Modi · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 92602026-06-01 · 15:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-734
    T. Mok, S. Modi · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 97302026-06-04 · 21:00 CT · E450
    KEYNOTE-139: Keytruda (pembrolizumab) maintenance in NSCLC
    J. Cortes, H. Rugo, S. Peters, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract 92012026-06-01 · 13:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-541
    S. Peters, J. Cortes · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract 96892026-06-04 · 15:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-255
    E. Winer, M. Krop · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract 92542026-06-05 · 20:00 CT · S406
    PACIFIC-986: Imfinzi (durvalumab) 1L in NSCLC
    T. Mok, J. Cortes, S. Tolaney, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 93942026-06-03 · 21:15 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    H. Borghaei, M.C. Garassino, R. Herbst, et al. · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  57. Abstract 96562026-06-02 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-173 study)
    S. Modi, J. Brahmer, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 94702026-06-05 · 14:45 CT · S406
    PACIFIC-539: Imfinzi (durvalumab) adjuvant in NSCLC
    M. Krop, A. Spira, J. Brahmer, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  59. Abstract 92542026-06-05 · 20:15 CT · S100A
    KEYNOTE-198: Keytruda (pembrolizumab) neoadjuvant in SCLC
    L. Paz-Ares, G. Curigliano, J. Brahmer · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  60. Abstract 92342026-06-05 · 16:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-885 study)
    M. Krop, E. Winer, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 97812026-06-02 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-117
    P. Schmid, J. Brahmer, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 95682026-06-05 · 19:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-434 study)
    G. Curigliano, C. Saura, T. Mok · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  63. Abstract 99392026-06-05 · 13:45 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-592
    S. Tolaney, M. Krop · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 93222026-06-05 · 20:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-536 study)
    M.C. Garassino, C. Saura, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 96132026-06-05 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-688
    H. Rugo, T. Mok · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  66. Abstract 91602026-06-03 · 20:00 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-987
    M.C. Garassino, T. Mok · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 93472026-06-05 · 20:45 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-540
    R. Herbst, P. Schmid, F. Andre, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 96382026-06-01 · 14:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-925 study)
    J. Brahmer, G. Curigliano · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 90222026-06-01 · 20:30 CT · E450
    IMpower-365: Tecentriq (atezolizumab) maintenance in NSCLC
    R. Herbst, L. Paz-Ares, J. Brahmer · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 98542026-06-03 · 14:15 CT · E450
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-351
    C. Saura, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 99432026-06-01 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-761 study)
    S. Tolaney, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 98532026-06-02 · 14:00 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-962
    N. Rizvi, A. Spira, C. Saura, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 95372026-06-02 · 19:00 CT · E450
    Quality of life outcomes with Imfinzi in patients with SCLC
    H. Borghaei, T. Mok, H. Rugo, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  74. Abstract 99332026-06-05 · 13:30 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Antonia, T. Mok · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 94092026-06-02 · 13:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-759 study)
    R. Herbst, M. Reck, S. Peters, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 98572026-06-05 · 18:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-809 study)
    G. Curigliano, S. Tolaney, C. Saura · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 97542026-06-04 · 15:15 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-549
    E. Winer, M. Reck, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 95112026-06-01 · 19:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-362
    M.C. Garassino, J. Cortes · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 94482026-06-02 · 14:15 CT · Hall B1
    PACIFIC-346: Imfinzi (durvalumab) adjuvant in SCLC
    H. Rugo, M. Krop, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  80. Abstract 99452026-06-03 · 18:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-311
    J. Brahmer, R. Herbst, C. Saura, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 98542026-06-04 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-830 study)
    E. Winer, M.C. Garassino, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  82. Abstract 92092026-06-01 · 19:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-237 study)
    L. Paz-Ares, M.C. Garassino, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 99492026-06-03 · 13:15 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-676
    N. Rizvi, M. Krop, R. Herbst, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 96002026-06-04 · 18:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-755 study)
    N. Rizvi, P. Schmid, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  85. Abstract 93642026-06-01 · 20:00 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-867 study)
    C. Robert, S. Antonia, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 99952026-06-05 · 20:45 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    A. Spira, M.C. Garassino, S. Peters, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 92122026-06-05 · 13:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-971 study)
    H. Borghaei, C. Robert, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 95882026-06-02 · 18:45 CT · E450
    Long-term follow-up of Keytruda 3L+ for SCLC: KEYNOTE-349
    F. Andre, S. Tolaney, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  89. Abstract 91472026-06-02 · 21:15 CT · Hall B1
    FLAURA-985: Tagrisso (osimertinib) 1L in NSCLC
    P. Schmid, M.C. Garassino · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 95382026-06-03 · 20:00 CT · S406
    FLAURA-433: Tagrisso (osimertinib) 2L in NSCLC
    S. Modi, J. Cortes · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 92152026-06-05 · 14:00 CT · S100A
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-648
    J. Brahmer, C. Robert · Chinese University of Hong Kong
    Poster SessionLung Cancer—Small Cell📄🖼️
  92. Abstract 98792026-06-01 · 13:15 CT · S406
    CheckMate-718: Opdivo (nivolumab) maintenance in NSCLC
    H. Borghaei, M. Reck, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  93. Abstract 96262026-06-01 · 16:30 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-71
    T. Mok, C. Robert, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 94292026-06-04 · 21:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-637
    S. Modi, G. Curigliano, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 93642026-06-05 · 19:45 CT · E450
    CheckMate-799: Opdivo (nivolumab) 2L in NSCLC
    M. Reck, M. Krop · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 97982026-06-05 · 19:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-868
    G. Curigliano, E. Winer, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 92882026-06-05 · 16:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-51 study)
    J. Cortes, C. Robert, M. Krop · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  98. Abstract 91582026-06-04 · 15:00 CT · Hall B1
    FLAURA-11: Tagrisso (osimertinib) 3L+ in NSCLC
    L. Paz-Ares, C. Robert · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 94982026-06-01 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for NSCLC: KEYNOTE-725
    S. Modi, M. Krop · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 91802026-06-02 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-896
    C. Saura, S. Tolaney · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 99032026-06-01 · 20:45 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-412
    F. Andre, E. Winer, S. Modi · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  102. Abstract 99252026-06-03 · 14:30 CT · E450
    KEYNOTE-968: Keytruda (pembrolizumab) 3L+ in SCLC
    H. Borghaei, S. Peters, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  103. Abstract 90872026-06-03 · 19:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-872
    G. Curigliano, R. Herbst, M. Reck, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  104. Abstract 97872026-06-05 · 19:15 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-780
    M. Krop, H. Rugo · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 95122026-06-03 · 20:30 CT · E450
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-807
    G. Curigliano, S. Modi, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 97352026-06-01 · 18:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-168 study)
    S. Antonia, F. Andre · Massachusetts General Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  107. Abstract 90922026-06-05 · 18:30 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-913
    R. Herbst, S. Peters · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  108. Abstract 91252026-06-04 · 13:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-29
    R. Herbst, C. Saura, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 93202026-06-02 · 15:30 CT · S406
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-50
    L. Paz-Ares, F. Andre, S. Peters · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  110. Abstract 91492026-06-04 · 15:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-882
    E. Winer, R. Herbst, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 98702026-06-05 · 18:15 CT · S100A
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-999
    S. Tolaney, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 99712026-06-02 · 18:45 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-498 study)
    R. Herbst, S. Modi, N. Rizvi, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  113. Abstract 95202026-06-03 · 18:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-531
    C. Robert, R. Herbst · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 91452026-06-04 · 13:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-873
    G. Curigliano, M. Reck · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  115. Abstract 97472026-06-01 · 13:00 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-555
    N. Rizvi, H. Borghaei, T. Mok, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 93392026-06-01 · 13:15 CT · E450
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-876
    A. Spira, J. Brahmer, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 98632026-06-01 · 21:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-947 study)
    J. Cortes, F. Andre, H. Rugo, et al. · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  118. Abstract 98842026-06-02 · 13:00 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-26
    H. Borghaei, M.C. Garassino, P. Schmid, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 94462026-06-04 · 20:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-494
    J. Cortes, L. Paz-Ares · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract 95672026-06-02 · 13:15 CT · E450
    KEYNOTE-889: Keytruda (pembrolizumab) adjuvant in SCLC
    M. Reck, G. Curigliano, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  121. Abstract 99172026-06-04 · 14:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-268 study)
    A. Spira, M.C. Garassino, P. Schmid, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  122. Abstract 96952026-06-03 · 16:15 CT · S406
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-717
    C. Saura, S. Antonia, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  123. Abstract 96172026-06-04 · 13:45 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    C. Saura, R. Herbst, S. Modi · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  124. Abstract 93272026-06-01 · 18:00 CT · S100A
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-62
    C. Robert, L. Paz-Ares, F. Andre, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 94632026-06-02 · 20:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-889 study)
    P. Schmid, E. Winer, G. Curigliano, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  126. Abstract 97362026-06-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-610 study)
    P. Schmid, N. Rizvi, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 98302026-06-01 · 15:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-378
    R. Herbst, H. Rugo, S. Antonia · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  128. Abstract 95972026-06-01 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-345 study)
    C. Robert, P. Schmid · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  129. Abstract 90282026-06-03 · 13:30 CT · S406
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-481
    T. Mok, S. Peters · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  130. Abstract 92952026-06-03 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-264 study)
    M.C. Garassino, R. Herbst, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  131. Abstract 90472026-06-01 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-426
    E. Winer, F. Andre, J. Brahmer, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 91612026-06-03 · 13:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-476 study)
    G. Curigliano, S. Antonia, R. Herbst, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  133. Abstract 96722026-06-04 · 16:00 CT · S406
    IMpower-551: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    S. Modi, G. Curigliano, A. Spira, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 90512026-06-05 · 20:15 CT · S100A
    FLAURA-384: Tagrisso (osimertinib) 3L+ in NSCLC
    J. Cortes, S. Tolaney, S. Modi · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 93102026-06-04 · 20:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-636
    C. Robert, S. Modi, H. Borghaei · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 96882026-06-04 · 18:15 CT · E450
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-494
    M. Krop, N. Rizvi, H. Borghaei · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  137. Abstract 96882026-06-03 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-592 study)
    H. Borghaei, M. Krop, F. Andre, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  138. Abstract 94192026-06-05 · 21:30 CT · S100A
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-15
    C. Robert, S. Modi, H. Rugo, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 92812026-06-02 · 13:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-517
    J. Cortes, C. Saura, M. Krop, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 97992026-06-03 · 20:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-354
    F. Andre, M.C. Garassino, S. Antonia, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  141. Abstract 92592026-06-05 · 14:45 CT · Hall B1
    PACIFIC-62: Imfinzi (durvalumab) 3L+ in NSCLC
    M.C. Garassino, M. Reck, S. Modi, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract 96032026-06-02 · 14:45 CT · S406
    PACIFIC-351: Imfinzi (durvalumab) 1L in SCLC
    C. Robert, H. Rugo, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  143. Abstract 94622026-06-02 · 19:15 CT · E450
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-337
    E. Winer, L. Paz-Ares, C. Saura · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  144. Abstract 90402026-06-03 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-447
    N. Rizvi, S. Modi, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  145. Abstract 94292026-06-02 · 21:15 CT · S100A
    FLAURA-28: Tagrisso (osimertinib) neoadjuvant in NSCLC
    C. Saura, F. Andre, S. Antonia · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  146. Abstract 92542026-06-01 · 21:15 CT · S406
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-814
    N. Rizvi, R. Herbst, P. Schmid, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  147. Abstract 93422026-06-03 · 13:00 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-749 study)
    S. Tolaney, J. Brahmer, R. Herbst · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  148. Abstract 94802026-06-01 · 14:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-143
    G. Curigliano, J. Brahmer, S. Antonia · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  149. Abstract 93182026-06-01 · 21:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-756
    M. Krop, P. Schmid, R. Herbst · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  150. Abstract 93032026-06-03 · 19:45 CT · Arie Crown Theater
    IMpower-522: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Peters, A. Spira · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  151. Abstract 97822026-06-01 · 21:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-833 study)
    S. Peters, E. Winer, S. Modi, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  152. Abstract 94292026-06-03 · 20:15 CT · E450
    IMpower-340: Tecentriq (atezolizumab) 1L in NSCLC
    S. Peters, T. Mok, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  153. Abstract 90682026-06-01 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-186 study)
    S. Tolaney, J. Brahmer, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  154. Abstract 90132026-06-01 · 13:30 CT · S406
    DESTINY-Breast-137: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    S. Tolaney, S. Modi, H. Rugo, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 99732026-06-04 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-162 study)
    A. Spira, M. Krop, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  156. Abstract 94822026-06-04 · 19:45 CT · E450
    KEYNOTE-521: Keytruda (pembrolizumab) 2L in NSCLC
    E. Winer, C. Robert · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  157. Abstract 99042026-06-03 · 15:15 CT · S406
    Long-term follow-up of Keytruda 2L for NSCLC: KEYNOTE-495
    S. Peters, T. Mok · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  158. Abstract 91272026-06-01 · 16:15 CT · Arie Crown Theater
    FLAURA-476: Tagrisso (osimertinib) maintenance in NSCLC
    M.C. Garassino, M. Reck · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  159. Abstract 94612026-06-01 · 13:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-457 study)
    G. Curigliano, S. Tolaney, R. Herbst, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  160. Abstract 99062026-06-02 · 18:30 CT · S100A
    KEYNOTE-291: Keytruda (pembrolizumab) adjuvant in SCLC
    C. Robert, N. Rizvi · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  161. Abstract 95992026-06-05 · 20:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-312 study)
    T. Mok, J. Brahmer, M. Reck, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  162. Abstract 97532026-06-02 · 18:00 CT · S100A
    CheckMate-479: Opdivo (nivolumab) 3L+ in NSCLC
    S. Peters, F. Andre, A. Spira · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  163. Abstract 99112026-06-03 · 21:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-813
    J. Cortes, F. Andre, C. Robert, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  164. Abstract 93712026-06-04 · 20:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-851
    E. Winer, N. Rizvi, L. Paz-Ares · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  165. Abstract 97502026-06-02 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-742 study)
    M.C. Garassino, H. Rugo · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  166. Abstract 90732026-06-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-633 study)
    M. Krop, L. Paz-Ares, S. Antonia · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  167. Abstract 91052026-06-03 · 15:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-919
    G. Curigliano, M.C. Garassino, S. Modi, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  168. Abstract 99692026-06-03 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-720 study)
    M. Reck, E. Winer, J. Brahmer, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 93882026-06-01 · 21:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-626 study)
    N. Rizvi, G. Curigliano, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  170. Abstract 90492026-06-05 · 21:30 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-870
    H. Rugo, S. Peters · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  171. Abstract 97522026-06-01 · 13:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-300 study)
    G. Curigliano, C. Robert · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  172. Abstract 96222026-06-03 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-620
    S. Tolaney, C. Robert · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  173. Abstract 97902026-06-03 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-722
    R. Herbst, H. Rugo · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  174. Abstract 96672026-06-04 · 14:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-985 study)
    J. Cortes, H. Borghaei · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  175. Abstract 92742026-06-02 · 19:45 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-704
    P. Schmid, A. Spira, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  176. Abstract 93822026-06-04 · 13:15 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-906
    E. Winer, H. Borghaei · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  177. Abstract 95542026-06-03 · 18:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-523 study)
    E. Winer, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  178. Abstract 99862026-06-04 · 14:00 CT · E450
    PACIFIC-962: Imfinzi (durvalumab) 2L in NSCLC
    S. Peters, M. Krop · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  179. Abstract 95112026-06-05 · 13:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-824
    S. Antonia, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  180. Abstract 99252026-06-01 · 14:45 CT · E450
    FLAURA-213: Tagrisso (osimertinib) neoadjuvant in NSCLC
    G. Curigliano, C. Robert, M. Reck, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  181. Abstract 96822026-06-04 · 18:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-545
    S. Tolaney, P. Schmid · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 90242026-06-01 · 19:15 CT · Arie Crown Theater
    KEYNOTE-18: Keytruda (pembrolizumab) 3L+ in NSCLC
    T. Mok, C. Robert, C. Saura, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  183. Abstract 96992026-06-01 · 20:15 CT · E450
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-265
    M.C. Garassino, S. Peters, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  184. Abstract 91002026-06-03 · 15:15 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-229
    H. Borghaei, S. Peters, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  185. Abstract 90852026-06-05 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for NSCLC: KEYNOTE-703
    E. Winer, C. Robert, M.C. Garassino · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  186. Abstract 90042026-06-04 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-771 study)
    S. Modi, R. Herbst, P. Schmid · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  187. Abstract 93032026-06-04 · 15:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-865 study)
    F. Andre, S. Peters, H. Borghaei, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  188. Abstract 93982026-06-04 · 13:00 CT · Hall B1
    FLAURA-694: Tagrisso (osimertinib) maintenance in NSCLC
    E. Winer, M. Reck, H. Borghaei, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  189. Abstract 97902026-06-02 · 20:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-178
    T. Mok, C. Robert, E. Winer, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 95722026-06-05 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-568 study)
    P. Schmid, N. Rizvi, M. Krop · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract 95632026-06-05 · 16:15 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-455
    J. Brahmer, S. Peters · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  192. Abstract 91002026-06-01 · 18:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-682
    G. Curigliano, S. Antonia, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  193. Abstract 93012026-06-04 · 16:15 CT · Hall B1
    CheckMate-163: Opdivo (nivolumab) neoadjuvant in NSCLC
    S. Antonia, A. Spira, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  194. Abstract 92302026-06-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-309 study)
    P. Schmid, T. Mok, A. Spira, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  195. Abstract 99752026-06-05 · 13:15 CT · E450
    FLAURA-955: Tagrisso (osimertinib) adjuvant in NSCLC
    F. Andre, S. Peters, M. Krop, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  196. Abstract 94252026-06-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-634 study)
    E. Winer, M. Krop, T. Mok, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  197. Abstract 93832026-06-03 · 21:15 CT · S100A
    PACIFIC-892: Imfinzi (durvalumab) neoadjuvant in NSCLC
    C. Robert, H. Borghaei, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  198. Abstract 92172026-06-04 · 13:00 CT · S406
    KEYNOTE-170: Keytruda (pembrolizumab) neoadjuvant in NSCLC
    G. Curigliano, R. Herbst, H. Borghaei, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  199. Abstract 91832026-06-03 · 15:15 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-411
    T. Mok, M. Reck, A. Spira, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  200. Abstract 96642026-06-02 · 16:15 CT · E450
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-239
    S. Tolaney, A. Spira · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.